PMID- 20972729
OWN - NLM
STAT- MEDLINE
DCOM- 20110224
LR  - 20220410
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 38
IP  - 3
DP  - 2010 Dec
TI  - The effects of the receptor for advanced glycation end products (RAGE) on bone 
      metabolism under physiological and diabetic conditions.
PG  - 369-76
LID - 10.1007/s12020-010-9390-9 [doi]
AB  - It has been reported that AGEs and the receptor for AGEs (RAGEs) have been linked 
      to the pathogenesis of diabetic microangiopathy. However, the relationship 
      between RAGE and alteration in bone metabolism is unclear. Therefore, in order to 
      determine the role of RAGE in bone metabolism, we investigated the effects of 
      RAGE deletion on bone metabolism under physiological and diabetic conditions 
      using RAGE knockout mice (RAGE-KO). Eight-week-old male RAGE-KO and wild-type 
      littermates (WT) were intraperitoneally injected with either streptozotocin or 
      vehicle. Mice were classified into four groups: (1) nondiabetic WT; (2) 
      nondiabetic RAGE-KO; (3) diabetic WT; and (4) diabetic RAGE-KO. After 12 weeks of 
      streptozotocin or vehicle treatment, the physical properties of femora and the 
      static and dynamic parameters of bone histomorphometry of tibiae were assessed. 
      The deletion of RAGE affected neither body weights nor hemoglobin A1c levels. 
      RAGE deletion resulted in increased bone mineral density due to decreased 
      osteoclast function under physiological conditions that is no accumulation of 
      AGEs. In contrast, lacking RAGE did not affect the alteration in bone metabolism 
      under diabetic conditions, suggesting that AGEs-RAGE interaction may not be 
      involved in the pathogenesis of diabetic osteopenia, although RAGE plays a 
      crucial role in bone metabolism.
FAU - Hamada, Yasuhiro
AU  - Hamada Y
AD  - Division of Nephrology and Kidney Center, Kobe University School of Medicine, 
      Kobe, Japan. hamada@med.kobe-u.ac.jp
FAU - Kitazawa, Sohei
AU  - Kitazawa S
FAU - Kitazawa, Riko
AU  - Kitazawa R
FAU - Kono, Keiji
AU  - Kono K
FAU - Goto, Shunsuke
AU  - Goto S
FAU - Komaba, Hirotaka
AU  - Komaba H
FAU - Fujii, Hideki
AU  - Fujii H
FAU - Yamamoto, Yasuhiko
AU  - Yamamoto Y
FAU - Yamamoto, Hiroshi
AU  - Yamamoto H
FAU - Usami, Makoto
AU  - Usami M
FAU - Fukagawa, Masafumi
AU  - Fukagawa M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101023
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Receptor for Advanced Glycation End Products)
RN  - 0 (Receptors, Immunologic)
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Absorptiometry, Photon
MH  - Animals
MH  - Bone Density/genetics
MH  - Bone Diseases, Metabolic/etiology/genetics/metabolism
MH  - Bone and Bones/*metabolism/physiology
MH  - Diabetes Mellitus, Experimental/chemically 
      induced/complications/*metabolism/physiopathology
MH  - Glycation End Products, Advanced/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Receptor for Advanced Glycation End Products
MH  - Receptors, Immunologic/genetics/*physiology
MH  - Streptozocin
EDAT- 2010/10/26 06:00
MHDA- 2011/02/25 06:00
CRDT- 2010/10/26 06:00
PHST- 2010/06/14 00:00 [received]
PHST- 2010/08/20 00:00 [accepted]
PHST- 2010/10/26 06:00 [entrez]
PHST- 2010/10/26 06:00 [pubmed]
PHST- 2011/02/25 06:00 [medline]
AID - 10.1007/s12020-010-9390-9 [doi]
PST - ppublish
SO  - Endocrine. 2010 Dec;38(3):369-76. doi: 10.1007/s12020-010-9390-9. Epub 2010 Oct 
      23.